JERUSALEM, Jan 9 (Reuters) – The Omicron-adapted COVID-19 vaccine booster developed by Pfizer Inc (PFE.N) and BioNTech SE (22UAy.DE) sharply reduced hospitalizations among older patients, Israeli researchers said on Monday, in some of the first evidence of the jab's real-world effectiveness.
The study by researchers from healthcare provider Clalit, Ben-Gurion University of the Negev and Sapir College has not yet been peer reviewed.
It found an 81% reduction in hospitalizations among people aged 65 and older who had received the booster against those who had previously received at least two COVID vaccinations, but not the Omicron-adapted shot.
The study was carried out from the end of September until mid-December and looked at 622,701 people aged 65 and over who were eligible for the bivalent booster. Among them, 85,314, or 14%, had received it.
"Hospitalization due to Covid-19 occurred in 6 bivalent recipients and 297 participants who did not" receive it, the study said. "Death due to Covid-19 occurred in 1 bivalent recipient and 73 participants who did not."
Though the 86% drop in mortality was statistically borderline because of the relatively low death rates in the country, it was nonetheless significant, the researchers said.
"Participants who received the bivalent vaccine had lower hospitalization and mortality rates due to Covid-19 than non-recipients up to 70 days after vaccination."
While the bivalent vaccine targets the original strain and its BA.4/BA.5 Omicron subvariant, scientists have been closely watching another Omicron subvariant, XBB.1.5, which has been rapidly spreading in the United States.
Our Standards: The Thomson Reuters Trust Principles.
China on Saturday marked the first day of "chun yun", the 40-day period of Lunar New Year travel known pre-pandemic as the world's largest annual migration of people, bracing for a huge increase in travellers and the spread of COVID-19 infections.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved
